Royal Bank of Canada’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1
| Closed | – | – | 7746 |
|
|
2023
Q4 | $0 | Buy |
+1
| New | +$492 | ﹤0.01% | 7710 |
|
|
2023
Q3 | – | Hold |
0
| – | -$2K | – | 7742 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 6923 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$2.93K | – | 6961 |
|
|
2022
Q4 | $2K | Hold |
1
| – | – | ﹤0.01% | 6961 |
|
|
2022
Q3 | $3K | Buy |
+1
| New | +$3.93K | ﹤0.01% | 6944 |
|
|
2022
Q2 | – | Sell |
-2
| Closed | -$5.21K | – | 7822 |
|
|
2022
Q1 | $5K | Sell |
2
-4
| -67% | -$17.2K | ﹤0.01% | 7274 |
|
|
2021
Q4 | $36K | Buy |
6
+3
| +100% | +$23K | ﹤0.01% | 6558 |
|
|
2021
Q3 | $29K | Buy |
3
+2
| +200% | +$17.2K | ﹤0.01% | 6490 |
|
|
2021
Q2 | $14K | Sell |
1
-1
| -50% | -$16.4K | ﹤0.01% | 6750 |
|
|
2021
Q1 | $32K | Buy |
+2
| New | +$23.3K | ﹤0.01% | 6173 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7349 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 7013 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6980 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7116 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7202 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7229 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7177 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7206 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7007 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6832 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6886 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6971 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7045 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6819 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6870 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6823 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6614 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6559 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6711 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6855 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6818 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6756 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6455 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6325 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6162 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6177 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6193 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 6191 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 6298 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 5741 |
|
Other funds holding SEEL
WE
AI
GJL
MWM
SFWC
Royal Bank of Canada's SEEL Position: Q1 2024 in Review
Royal Bank of Canada sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 1 share.
Royal Bank of Canada first reported a position in SEEL in Q1 2021 and held it in 8 quarters. The position peaked at $36K in Q4 2021. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.
- Royal Bank of Canada reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Royal Bank of Canada sold 1 Seelos Therapeutics, Inc. Common Stock share in Q1 2024.
- Royal Bank of Canada first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
- Royal Bank of Canada's Seelos Therapeutics, Inc. Common Stock position peaked at $36K in Q4 2021.
- 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.